PEAK6 Investments’s Repligen RGEN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2023
Q2
– Sell
-291
Closed -$49K – 4575
2023
Q1
$49K Sell
291
-92
-24% -$16.4K ﹤0.01% 3752
2022
Q4
$64.8K Buy
+383
New +$69.5K ﹤0.01% 3817
2022
Q2
– Sell
-5,593
Closed -$1.05M – 5104
2022
Q1
$1.05M Buy
5,593
+3,902
+231% +$741K ﹤0.01% 2459
2021
Q4
$448K Buy
1,691
+1,689
+84,450% +$455K ﹤0.01% 3319
2021
Q3
$1K Sell
2
-3,462
-100% -$888K ﹤0.01% 5019
2021
Q2
$691K Sell
3,464
-2,822
-45% -$547K ﹤0.01% 2946
2021
Q1
$1.22M Buy
+6,286
New +$1.29M ﹤0.01% 2370
2020
Q4
– Sell
-721
Closed -$106K – 5052
2020
Q3
$106K Buy
+721
New +$103K ﹤0.01% 3824
2020
Q2
– Sell
-807
Closed -$94.9K – 4751
2020
Q1
$78K Buy
+807
New +$77.9K ﹤0.01% 3422

Other funds holding RGEN

PEAK6 Investments's RGEN Position: Q2 2023 in Review

PEAK6 Investments sold out of Repligen (RGEN) in Q2 2023, closing a stake of 291 shares — an estimated $49K sold.

PEAK6 Investments first reported a position in RGEN in Q1 2020 and held it in 9 quarters. The position peaked at $1.22M in Q1 2021. 446 funds tracked by Wall St. Rank hold RGEN as of Q2 2023.

  • PEAK6 Investments reported no remaining Repligen position as of Q2 2023 after selling out during the quarter.
  • PEAK6 Investments sold 291 Repligen shares in Q2 2023, an estimated $49K.
  • PEAK6 Investments first reported a position in Repligen in Q1 2020 and held it in 9 quarters.
  • PEAK6 Investments's Repligen position peaked at $1.22M in Q1 2021.
  • 446 funds tracked by Wall St. Rank held Repligen as of Q2 2023.

Based on PEAK6 Investments's 13F filing for Q2 2023, filed 11 Aug 2023.